Phase IIb study ZYN002 in adult with refractory focal epilepsy.
Phase of Trial: Phase II
Latest Information Update: 17 Dec 2018
At a glance
- Drugs Cannabidiol (Primary)
- Indications Partial epilepsies
- Focus Therapeutic Use
- 17 Dec 2018 According to the Zynerba Pharmaceuticals media release, the Company has decided to postpone the initiation of this trial until after reporting data from the four childhood neuropsychiatric studies.
- 09 Jan 2018 New trial record
- 03 Jan 2018 According to the Zynerba Pharmaceuticals media release, company intends to initiate this trial in the second half of 2018. The design of this study will be modified from the STAR 1 and STAR 2 trial design which includes increase in the number of patients enrolled, baseline seizure frequency, length of the study and also changes in randomization methodologies utilized.